EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Evolution of ceftazidime-avibactam resistance driven by variation in blaKPC-2 to blaKPC-190 during treatment of ST11-K64 hypervirulent Klebsiella pneumoniae

Zeshi Liu, Jing Lei, Xue Zhang, Jian Yin, Yanping Zhang, Ke Lei, Yan Geng, Lingjuan Huang, Qiang Han, Aili He

Frontiers in Cellular and Infection Microbiology · 06.06.2025 · 15

DOI: 10.3389/fcimb.2025.1607127 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Cellular and Infection Microbiology, online erschienen am 06.06.2025. Verfasst von Zeshi Liu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Laboratory, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China. Hauptthemen laut MEDLINE: Ceftazidime, Klebsiella pneumoniae, beta-Lactamases, Azabicyclo Compounds. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

The emergence of Klebsiella pneumoniae carbapenemase (KPC) variants has significantly compromised the efficacy of ceftazidime-avibactam (CZA), a critical antibiotic for treating carbapenem-resistant K. pneumoniae (CRKP) infections. This study investigates the novel KPC-190 variant, identified in a hypervirulent ST11-K64 K. pneumoniae strain during CZA therapy, which confers resistance to CZA while partially restoring carbapenem susceptibility.

Methods

The K. pneumoniae clinical isolate LX02 harboring bla KPC-190 was characterized using antimicrobial susceptibility testing, whole-genome sequencing (Illumina and Nanopore), and plasmid analysis. Functional studies included plasmid transformation, cloning assays, and enzyme kinetics (spectrophotometric analysis of purified KPC-190 protein). Genetic context was mapped using bioinformatics tools (RAST, ResFinder, Proksee), and virulence determinants were identified.

Results

KPC-190 exhibited a unique resistance profile: high-level CZA resistance (MIC >64 μg/mL) with reduced carbapenem MICs (imipenem MIC = 2 μg/mL). Enzyme kinetics revealed decreased K cat/Km for carbapenems and ceftazidime, alongside a 9-fold higher IC50 for avibactam (0.13 μM vs. KPC-2’s 0.014 μM). Genomic analysis identified bla KPC-190 within an IS26 flanked mobile element (IS26-ISKpn8- bla KPC -ΔISKpn6-ΔtnpR-IS26) on an IncFII plasmid. The strain also carried hypervirulence markers ( rmpA2 , iucABCD-iutA , and type 1/3 fimbriae).

Discussion

The KPC-190 variant underscores the adaptive evolution of bla KPC under antibiotic pressure, combining CZA resistance via enhanced ceftazidime affinity and avibactam evasion with retained carbapenem hydrolysis. Its association with hypervirulence plasmids and IS26-mediated mobility poses a dual threat for dissemination. These findings highlight the urgent need for genomic surveillance and alternative therapies (e.g., meropenem-vaborbactam) to address KPC-190-mediated resistance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CeftazidimeKlebsiella pneumoniaebeta-LactamasesAzabicyclo CompoundsAnti-Bacterial AgentsBacterial ProteinsDrug Resistance, Multiple, BacterialDrug CombinationsHumansKlebsiella InfectionsMicrobial Sensitivity TestsWhole Genome SequencingPlasmidsVirulenceGenome, Bacterial

Stichwörter der Autor:innen

KPC-190Klebsiella pneumoniaeantibiotic resistanceblaKPC variantsceftazidime-avibactam

Substanzen

Ceftazidimebeta-LactamasesAzabicyclo Compoundsavibactam, ceftazidime drug combinationDrug CombinationsAnti-Bacterial AgentsBacterial Proteinsbeta-lactamase KPC-2, Klebsiella pneumoniaecarbapenemase

Autor:innen und Institutionen

  • Department of Clinical Laboratory, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
  • Geriatrics Department, The First Affiliated Hospital of Xi'an Medical College, Xi'an, China.
  • Department of Gynaecology and Obstetrics, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
  • Department of Hematology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
  • National-Local Joint Engineering Research Center of Biodiagnostics and Biotherapy, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
  • Xi'an Key Laboratory of Hematological Diseases, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.

Zitieren

APA

Liu, Z., Lei, J., Zhang, X., Yin, J., Zhang, Y., Lei, K., Geng, Y., Huang, L., Han, Q., & He, A. (2025). Evolution of ceftazidime-avibactam resistance driven by variation in blaKPC-2 to blaKPC-190 during treatment of ST11-K64 hypervirulent Klebsiella pneumoniae. Frontiers in Cellular and Infection Microbiology, 15. https://doi.org/10.3389/fcimb.2025.1607127

Vancouver

Liu Z, Lei J, Zhang X, Yin J, Zhang Y, Lei K, et al. Evolution of ceftazidime-avibactam resistance driven by variation in blaKPC-2 to blaKPC-190 during treatment of ST11-K64 hypervirulent Klebsiella pneumoniae. Frontiers in Cellular and Infection Microbiology. 2025;15. doi:10.3389/fcimb.2025.1607127

BibTeX
@article{Liu2025,
  author = {Liu, Zeshi and Lei, Jing and Zhang, Xue and Yin, Jian and Zhang, Yanping and Lei, Ke and Geng, Yan and Huang, Lingjuan and Han, Qiang and He, Aili},
  title = {Evolution of ceftazidime-avibactam resistance driven by variation in blaKPC-2 to blaKPC-190 during treatment of ST11-K64 hypervirulent Klebsiella pneumoniae},
  journal = {Frontiers in Cellular and Infection Microbiology},
  year = {2025},
  volume = {15},
  doi = {10.3389/fcimb.2025.1607127}
}
Kostenlos starten →